In order to investigate the potential involvement of the PD‐1/PD‐L1 pathway in adaptive immune resistance after KDM4 inhibition, we measured PD‐L1 levels on tumour cells following JIB‐04 treatment or genetic deletion of KDM4B. Here, KDM4B is linked to neoplasm.